bromocriptine

Summary

Summary: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.

Top Publications

  1. Todisco M. Relapse of high-grade non-Hodgkin's lymphoma after autologous stem cell transplantation: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, melatonin, retinoids, and ACTH. Am J Ther. 2006;13:556-7 pubmed
    ..With a combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH, we already reported 100% global response in 8 patients with relapse of low-..
  2. Wang C, Su Z, Sanai N, Xue X, Lu L, Chen Y, et al. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment. Oncol Rep. 2012;27:1312-20 pubmed publisher
    Little is known about the function of microRNAs in prolactinomas treated with bromocriptine. The aim of the study was to explore the microRNAs associated with bromocriptine-treated prolactinomas...
  3. Dos Santos Silva C, Barbosa F, Lima G, Warszawski L, Fontes R, Domingues R, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011;19:800-5 pubmed publisher
  4. Todisco M. Low-grade non-Hodgkin lymphoma at advanced stage: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, retinoids, and melatonin. Am J Ther. 2007;14:113-5 pubmed
    ..Today, 18 months after the beginning of treatment, the patient is in complete remission. Treatment had very good tolerance, and the patient carried on at home doing his normal activities. ..
  5. Reed D, Johnson N, Thompson C, Weintraub S, Mesulam M. A clinical trial of bromocriptine for treatment of primary progressive aphasia. Ann Neurol. 2004;56:750 pubmed
  6. Gibbs S, D ESPOSITO M. A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory. Psychopharmacology (Berl). 2005;180:644-53 pubmed
    ..In this study we tested the effects of the D2 dopamine agonist bromocriptine during the performance of a delayed recognition task using functional magnetic resonance imaging (fMRI)...
  7. de Leeuw van Weenen J, Parlevliet E, Maechler P, Havekes L, Romijn J, Ouwens D, et al. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010;79:1827-36 pubmed publisher
    Treatment with the dopamine receptor D2 (DRD2) agonist bromocriptine improves metabolic features in obese patients with type 2 diabetes by a still unknown mechanism...
  8. Vautier S, Lacomblez L, Chacun H, Picard V, Gimenez F, Farinotti R, et al. Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. Eur J Pharm Sci. 2006;27:167-74 pubmed
    ..In vivo, at the mouse BBB level and in our experimental conditions, bromocriptin is a Pgp substrate but is not a Pgp modulator. ..
  9. Casteels C, Vanbilloen B, Vercammen D, Bosier B, Lambert D, Bormans G, et al. Influence of chronic bromocriptine and levodopa administration on cerebral type 1 cannabinoid receptor binding. Synapse. 2010;64:617-23 pubmed publisher
    ..study was to investigate the in vivo effect of the commonly used antiparkinsonian drugs, levodopa (L-DOPA) and bromocriptine, on type 1 cannabinoid (CB1) receptors, using the PET radioligand [(18)F]MK-9470...

More Information

Publications62

  1. Kirsch P, Reuter M, Mier D, Lonsdorf T, Stark R, Gallhofer B, et al. Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett. 2006;405:196-201 pubmed
    ..crossover study with 24 participants we found an increase of reward system activation from placebo to bromocriptine only in subjects carrying the A1 allele...
  2. Wu Z, Zheng W, Su Z, Chen Y, Wu J, Wang C, et al. Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. J Neurooncol. 2010;99:25-32 pubmed publisher
    ..as responsive (14 cases) or resistant (six cases) according to their clinical and biochemical response to bromocriptine. Tumor tissue samples were examined by means of QRT-PCR analysis...
  3. Yuan H, Wang C, Sze C, Tong Y, Tan Q, Feng X, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol. 2008;28:264-370 pubmed publisher
    ..This study was designed to compare the herbal preparation called Peony-Glycyrrhiza Decoction (PGD) with bromocriptine (BMT), a dopamine agonist widely used for PRL-secreting disorders, in the treatment of risperidone-induced ..
  4. Holt R, Barnett A, Bailey C. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab. 2010;12:1048-57 pubmed publisher
    b>Bromocriptine is an ergot alkaloid dopamine D(2) receptor agonist that has been used extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism...
  5. Spitzer D, Wogatzky J, Murtinger M, Zech M, Haidbauer R, Zech N. Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2011;95:2742-4.e1 pubmed publisher
    The aim of this retrospective study is to investigate the frequency and severity of ovarian hyperstimulation syndrome and the pregnancy rate in a patient collective at risk who received bromocriptine treatment.
  6. Norsa A, Martino V. Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status. Cancer Biother Radiopharm. 2007;22:50-5 pubmed
    ..Oncology Group PS > or = 2, received a daily combination of somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide. Twenty-three (23) patients were enrolled. The median age was 59 years (range, 42-75)...
  7. Kim M, Rhee J, Lee S, Kwon S, Lee C. Akinetic mutism responsive to bromocriptine following subdural hematoma evacuation in a patient with hydrocephalus. Neurol Med Chir (Tokyo). 2007;47:419-23 pubmed
    ..Postoperatively, the patient developed akinetic mutism, but her condition improved after administration of bromocriptine. Absence of abnormalities on dopamine transporter single photon emission computed tomography, lack of clinical ..
  8. Barroso B, Bigou P, Martin K, Lippa A, Chabouni L, Dakar A, et al. [Reversible postpartum cerebral angiopathy associated with bromocriptine therapy]. Rev Neurol (Paris). 2004;160:1191-3 pubmed
    Postpartum is known to be an important risk factor for stroke. Bromocriptine may induce cerebral angiopathy...
  9. Vautier S, Milane A, Fernandez C, Chacun H, Lacomblez L, Farinotti R. Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration. J Pharm Pharm Sci. 2009;12:199-208 pubmed
    ..MPTP-induced dopaminergic degeneration is an experimental model commonly used to explore Parkinson's disease. Cerebral drug transport by ABC transporters in MPTP models has never been reported...
  10. Lu S, Callahan S, Jin R, Brunner L. Cyclosporine and bromocriptine-induced suppressions of CYP3A1/2 and CYP2C11 are not mediated by prolactin. Eur J Pharmacol. 2004;501:215-24 pubmed
    ..vehicle concomitantly with one of the following: 500 mg/kg prolactin, 1 ml/kg prolactin vehicle, 4 mg/kg bromocriptine, or 1 ml/kg bromocriptine vehicle for 14 days...
  11. Mukherjee R, Yun J. Bromocriptine inhibits adipogenesis and lipogenesis by agonistic action on ?2-adrenergic receptor in 3T3-L1 adipocyte cells. Mol Biol Rep. 2013;40:3783-92 pubmed publisher
    The primary goals of the present study were to investigate the inhibitory effects of bromocriptine (BC) on adipogenesis and lipogenesis in 3T3-L1 adipocyte cells as well as to elucidate its molecular mechanism of action...
  12. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema J, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121:1465-73 pubmed publisher
    ..Previous reports suggest that bromocriptine may have beneficial effects in women with acute onset of PPCM...
  13. Todisco M. Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH. Cancer Biother Radiopharm. 2009;24:353-5 pubmed publisher
    ..with previously untreated progressive stage I Rai CCL, with a combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH...
  14. Habedank D, Kühnle Y, Elgeti T, Dudenhausen J, Haverkamp W, Dietz R. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur J Heart Fail. 2008;10:1149-51 pubmed publisher
    ..may induce myocardial damage, and this offered a new option of treating PPCM by blocking prolactin with bromocriptine. We report on a 35-year-old woman with a twin gravidity who gave birth to two healthy boys at day 36/6 and ..
  15. Jahns B, Stein W, Hilfiker Kleiner D, Pieske B, Emons G. Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion. Am J Obstet Gynecol. 2008;199:e5-6 pubmed publisher
    ..Recent experimental data implicate a causal role of prolactin. We report a patient with PPCM who responded well to treatment with Bromocriptine in addition to standard therapy of heart failure.
  16. Heidari Z, Hosseinpanah F, Shirazian N. Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor. Endocr Pract. 2010;16:669-72 pubmed publisher
    ..the achievement of fertility in an infertile man with a resistant macroprolactinoma by using high-dose bromocriptine and a combination of human chorionic gonadotropin (hCG) and an aromatase inhibitor...
  17. Motazedian S, Babakhani L, Fereshtehnejad S, Mojthahedi K. A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. Indian J Med Res. 2010;131:670-4 pubmed
    The aim of this study was to compare the effects of bromocriptine versus cabergoline on pregnancy in hyperprolactinaemic infertile women...
  18. Shirasaki Y, Sugimura M, Sato T. Bromocriptine, an ergot alkaloid, inhibits excitatory amino acid release mediated by glutamate transporter reversal. Eur J Pharmacol. 2010;643:48-57 pubmed publisher
    b>Bromocriptine, a dopamine D(2) receptor agonist, has widely been used for patients with Parkinson's disease. The aim of the present study was to investigate the effect of bromocriptine on glutamate transporter...
  19. Castro Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, et al. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord. 2006;21:500-9 pubmed
    ..12-month international, randomized, double-blind trial aimed to assess the efficacy of piribedil 150 mg versus bromocriptine 25 mg, in early combination with levodopa in Stage I to III PD patients...
  20. Kerr J, Timpe E, Petkewicz K. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Ann Pharmacother. 2010;44:1777-85 pubmed publisher
    To review the pharmacologic characteristics, safety, and efficacy of bromocriptine mesylate for glycemic control in patients with type 2 diabetes mellitus...
  21. González Mariscal G, Chirino R, Flores Alonso J, Rosenblatt J, Beyer C. Intracerebroventricular injections of prolactin counteract the antagonistic effect of bromocriptine on rabbit maternal behaviour. J Neuroendocrinol. 2004;16:949-55 pubmed
    ..c.v.) to primiparous animals injected with bromocriptine subcutaneously (s.c.). Control females (given vehicle s.c. and i.c.v...
  22. Casulari L, Naves L, Mello P, Pereira Neto A, Papadia C. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res. 2004;62:300-5 pubmed
    ..Later, cabergoline was substituted by bromocriptine (7...
  23. DeFronzo R. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34:789-94 pubmed publisher
  24. Tanaka K, Kanno T, Yanagisawa Y, Yasutake K, Hadano S, Yoshii F, et al. Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2011;232:41-52 pubmed publisher
    ..Using this system, we identified the dopamine D2 receptor agonist bromocriptine (BRC) as one of NAIP-upregulating compounds...
  25. Kang S, Kim M, Shin I, Park D, Sohn J, Yoon Y. Bromocriptine for control of hyperthermia in a patient with mixed autonomic hyperactivity after neurosurgery: a case report. J Korean Med Sci. 2012;27:965-8 pubmed publisher
    ..An extensive evaluation of the sustained fever was conducted. Finally, the cause for MAHD was suspected, and the patient was successfully treated with bromocriptine for a month.
  26. Thondam S, Alusi S, O Driscoll K, Gilkes C, Cuthbertson D, Daousi C. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. Clin Neuropharmacol. 2013;36:170-2 pubmed publisher
    ..We describe a young patient with severe, socially disruptive impulsivity manifesting with pathological gambling who had been on long-term bromocriptine therapy for a macroprolactinoma.
  27. Fett J. Caution in the use of bromocriptine in peripartum cardiomyopathy. J Am Coll Cardiol. 2008;51:2083; author reply 2083-4 pubmed publisher
  28. Goyal N, Gore M, Shankar R. Galactorrhea and amenorrhea in burn patients. Burns. 2008;34:825-8 pubmed publisher
    ..Galactorrhea and/or amenorrhea, although uncommonly reported in post-burn patients, is a complex problem to treat. Patient is reluctant to volunteer history of these symptoms, unless asked specifically...
  29. Gibbs S, D ESPOSITO M. Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation. Cogn Affect Behav Neurosci. 2005;5:212-21 pubmed
    ..Subjects performed a verbal delayed-recognition task after taking either the dopamine receptor agonist bromocriptine or a placebo...
  30. Yavasoglu I, Kucuk M, Coskun A, Guney E, Kadikoylu G, Bolaman Z. Polycystic ovary syndrome and prolactinoma association. Intern Med. 2009;48:611-3 pubmed
    ..Pituitary MRI showed 6x8 mm microadenoma at left half. Bromocriptine was started with 1.25 mg/day and increased to 5 mg/day...
  31. Vinik A, Cincotta A, Scranton R, Bohannon N, Ezrokhi M, Gaziano J. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract. 2012;18:931-43 pubmed publisher
    To investigate the effect of Bromocriptine-QR on glycemic control in patients with type 2 diabetes whose glycemia is poorly controlled on one or two oral anti-diabetes agents...
  32. Kline A, Massucci J, Ma X, Zafonte R, Dixon C. Bromocriptine reduces lipid peroxidation and enhances spatial learning and hippocampal neuron survival in a rodent model of focal brain trauma. J Neurotrauma. 2004;21:1712-22 pubmed
    ..The present study examined the neuroprotective effects of bromocriptine (BRO), a dopamine D2 receptor agonist with significant antioxidant properties, on cognition, histopathology, ..
  33. Dos Santos Nunes V, El Dib R, Boguszewski C, Nogueira C. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011;14:259-65 pubmed publisher
    Cabergoline and bromocriptine are the most used drugs in the treatment of hyperprolactinemia, they are able to normalize the prolactin levels, restore gonadal function and promote tumor reduction in the majority of patients...
  34. Mohanasundari M, Srinivasan M, Sethupathy S, Sabesan M. Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice. J Neurol Sci. 2006;249:140-4 pubmed
    The present study has been designed to evaluate the combined effect of bromocriptine (BRC) and Hypericum perforatum extract (HPE) on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease in male Swiss Albino ..
  35. Wu Z, Yu C, Su Z, Zhuge Q, Wu J, Zheng W. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg. 2006;104:54-61 pubmed
    The aim of this study was to observe long-term clinical outcomes in a group of patients treated with bromocriptine for invasive giant prolactinomas involving the cavernous sinus...
  36. Cools R, Frank M, Gibbs S, Miyakawa A, Jagust W, D ESPOSITO M. Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. J Neurosci. 2009;29:1538-43 pubmed publisher
    ..The D(2) receptor agonist bromocriptine improved reward-based relative to punishment-based reversal learning in subjects with low baseline dopamine ..
  37. Kok P, Roelfsema F, Frolich M, van Pelt J, Meinders A, Pijl H. Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese women. J Clin Endocrinol Metab. 2006;91:3236-40 pubmed
    ..This study was done to establish the effect of bromocriptine treatment on circadian plasma leptin concentrations in obese humans...
  38. Mejía Rodríguez O, Alvarez Aguilar C, Ledesma Ramírez M, Paniagua Sierra R. Therapeutic effect of bromocriptine together with the established treatment for hypertension in patients undergoing peritoneal dialysis. Proc West Pharmacol Soc. 2004;47:122-4 pubmed
  39. McAllister T, Flashman L, McDonald B, Ferrell R, Tosteson T, Yanofsky N, et al. Dopaminergic challenge with bromocriptine one month after mild traumatic brain injury: altered working memory and BOLD response. J Neuropsychiatry Clin Neurosci. 2011;23:277-86 pubmed publisher
    ..healthy controls (HC) and 26 individuals with mild TBI (MTBI) 1 month after injury were challenged with bromocriptine versus placebo before administration of a verbal WM functional MRI task...
  40. Rokem A, Landau A, Prinzmetal W, Wallace D, Silver M, D ESPOSITO M. Modulation of inhibition of return by the dopamine D2 receptor agonist bromocriptine depends on individual DAT1 genotype. Cereb Cortex. 2012;22:1133-8 pubmed publisher
    ..examined the role of DA in involuntary attention and IOR by administering the DA D2 receptor-specific agonist bromocriptine to healthy human subjects...
  41. Kok P, Roelfsema F, Frolich M, van Pelt J, Stokkel M, Meinders A, et al. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab. 2006;291:E1038-43 pubmed
    ..We studied the acute effects of bromocriptine (a D2R agonist) on energy metabolism in obese women; body weight and caloric intake remained constant...
  42. Aydin Y, Atis A, Kaleli S, Uludag S, Goker N. Cabergoline versus bromocriptine for symptomatic treatment of premenstrual mastalgia: a randomised, open-label study. Eur J Obstet Gynecol Reprod Biol. 2010;150:203-6 pubmed publisher
    To compare the effectiveness and side effects of cabergoline with bromocriptine for the symptomatic treatment of cyclic mastalgia as a part of the premenstrual syndrome...
  43. Lim J, Kim K, Kim S, Hwang O, Choi H. Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage. Pharmacol Res. 2008;57:325-31 pubmed publisher
    ..The dopamine agonist bromocriptine is used clinically for PD therapy...
  44. Lee M, Song H, An H, Yang J, Ko Y, Jung I, et al. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study. Psychiatry Clin Neurosci. 2010;64:19-27 pubmed publisher
    The objective of the present study was to assess the efficacy and safety of bromocriptine treatment for patients with antipsychotic-drug-induced hyperprolactinemia in clinical practice...
  45. Davis L, Michaelides M, Cheskin L, Moran T, Aja S, Watkins P, et al. Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity. Neuroendocrinology. 2009;89:152-62 pubmed publisher
    The dopamine (DA) D(2) receptor (D2R) agonist bromocriptine (BC) decreases body fat in animal and human models and increases lean muscle mass, improves glucose intolerance and insulin resistance, and reduces triglycerides and free fatty ..
  46. Li H, Shi S, Sun Y, Zhao Y, Li Q, Li H, et al. Dopamine D2 receptor stimulation inhibits angiotensin II-induced hypertrophy in cultured neonatal rat ventricular myocytes. Clin Exp Pharmacol Physiol. 2009;36:312-8 pubmed publisher
    ..Therefore, the effects of the D2 receptor agonist bromocriptine and the D2 receptor antagonist haloperidol on angiotensin (Ang) II- or endothelin (ET)-1-induced hypertrophy ..
  47. Colao A, Di Sarno A, Guerra E, De Leo M, Mentone A, Lombardi G. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab. 2006;2:200-10 pubmed
    ..Primary therapy of prolactinomas is based on use of dopamine-receptor agonists. Bromocriptine induces normalization of prolactin levels in 80-90% of patients with microprolactinomas and approximately 70% ..
  48. Chiasson K, Daoust B, Levesque D, Martinoli M. Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ -induced toxicity in PC12 cells. Neurotox Res. 2006;10:31-42 pubmed
    ..Using colorimetric assays, western blots and reverse transcriptase-PCR, we demonstrated that two D2 agonists, bromocriptine and quinpirole, consistently increased MPP+ -induced cytotoxicity in both differentiated and undifferentiated ..
  49. Gruszka A, Kunert Radek J, Radek A, Pisarek H, Taylor J, Dong J, et al. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro. Life Sci. 2006;78:689-93 pubmed
    ..The effects of native SST (SST-14), a SST/DA chimera (BIM-23A387) and a D(2)-dopamine receptor agonist bromocriptine (BC) were also examined...
  50. Bliesener N, Yokusoglu H, Quednow B, Klingmuller D, Kühn K. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report. Pharmacopsychiatry. 2004;37:189-91 pubmed
  51. Oranje B, Gispen de Wied C, Westenberg H, Kemner C, Verbaten M, Kahn R. Increasing dopaminergic activity: effects of L-dopa and bromocriptine on human sensory gating. J Psychopharmacol. 2004;18:388-94 pubmed
    ..25 mg bromocriptine (D2 agonist) or placebo (n=17). Subsequently, they were tested for their sensory gating (P50 suppression)...
  52. Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M. Does bromocriptine improve glycemic control of obese type-2 diabetics?. Horm Res. 2004;62:55-9 pubmed
    ..In recent years, bromocriptine has been tried with controversial results...
  53. Levy M, Matharu M, Meeran K, Powell M, Goadsby P. The clinical characteristics of headache in patients with pituitary tumours. Brain. 2005;128:1921-30 pubmed
    ..A proposed modification of the current classification of pituitary-associated headache is given. ..